Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | BACE1 | P56817 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | ESR1 | P03372 | 3/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TYMS | P04818 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2085052 | 0.91 | KCNH2 (0.48) | KCNH2BACE1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3989982 | 0.87 | BACE1 (0.44) | KCNH2BACE1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2086657 | 0.77 | BACE1 (0.56) | KCNH2BACE1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2084875 | 0.76 | BACE1 (0.43) | KCNH2BACE1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15282105 | 0.70 | BACE1 (0.44) | KCNH2BACE1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL8225687 | 0.69 | BACE1 (0.44) | KCNH2BACE1 | |
| SCHEMBL2086015 | 0.69 | BACE1 (0.46) | KCNH2BACE1KMT2ATP53 | |
| SCHEMBL5678731 | 0.68 | MEN1 (0.50) | KCNH2MEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL28634795 | 0.64 | MEN1 (0.49) | KCNH2MEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL8984568 | 0.64 | MEN1 (0.81) | KCNH2MEN1KMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2345411-B1 | Heterocyclic aspartyl protease inhibitors, preparation and use thereof | MERCK SHARP & DOHME (US) | 2013-10-02 | — | — | EP | claimed |
| US-20110059992-A1 | New Compounds | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | claimed |
| CN-101506162-A | Substituted isoindoles as bace inhibitors and their use | ASTRAZENECA AB (SE) | 2009-08-12 | — | — | CN | claimed |
| EP-2035378-A1 | SUBSTITUTED ISOINDOLES AS BACE INHIBITORS AND THEIR USE | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | claimed |
| US-20080171771-A1 | New Compounds 391 | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | claimed |
| WO-2007149033-A1 | SUBSTITUTED ISOINDOLES AS BACE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | WO | claimed |
| CN-101506162-B | Substituted isoindoles as bace inhibitors and their use | ASTRAZENECA AB | 2012-06-27 | — | — | CN | disclosed |
| US-20110059992-A1 | New Compounds | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| US-7855213-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-12-21 | — | — | US | disclosed |
| CN-101506162-A | Substituted isoindoles as bace inhibitors and their use | ASTRAZENECA AB (SE) | 2009-08-12 | — | — | CN | disclosed |
| EP-2035378-A1 | SUBSTITUTED ISOINDOLES AS BACE INHIBITORS AND THEIR USE | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| US-20080171771-A1 | New Compounds 391 | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2007149033-A1 | SUBSTITUTED ISOINDOLES AS BACE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059992-A1 | New Compounds | MAPT, PSEN2, PSEN1 | KCNH2 3126/4885BACE1 5/4885MEN1 3163/4885 |
| US-20080171771-A1 | New Compounds 391 | PSEN2, PSEN1, MAPT | KCNH2 2710/4885BACE1 4/4885MEN1 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.